No Objections to Better Premiums, Easing of Re-Pricing as Incentives for Pediatric Drug Development: Chuikyo

A key Japanese reimbursement policy panel on November 22 deliberated on a series of drug pricing measures for incentivizing the development of pediatric medicines, such as increased premium rates in initial listing. No objections were raised by members towards these...read more